Ghrelin in Cystic Fibrosis (ghrelin)
The Effect of Ghrelin on Appetite and Immune Function in Patients With Cystic Fibrosis
Background to ghrelin Ghrelin is a naturally occurring hormone found in the blood which stimulates appetite. In healthy individuals, levels of ghrelin are high before a meal and falls afterwards. Previous studies have shown that giving ghrelin (by injection) to thin patients with renal failure and cancer increases their food intake. Furthermore, addition of ghrelin may also reduce inflammation within the body. Cystic Fibrosis (CF) is a genetic disease which frequently results in recurrent lung infections (leading to progressive inflammatory lung damage) and low body weight. Low body weight in CF is associated with increased lung infections, rapidly worsening lung function and a shortened life expectancy.
The researchers postulate that administration of extra ghrelin to CF patients with low body weight may increase food intake and reduce lung inflammation. If successful, this study might identify ghrelin as a potential therapy for CF patients to improve nutrition, decrease lung inflammation and thereby improve survival.
Studieoversikt
Detaljert beskrivelse
The purpose of this study is to investigate the role of a naturally occuring hormone called ghrelin on appetite, energy expenditure and immune function in patients with cystic fibrosis.
Theoretical framework:
Despite advances in the molecular understanding of the disease, life-expectancy in Cystic Fibrosis (CF) remains severely limited. Reduced body-weight is associated with increased inflammatory lung damage and is a major predictor of mortality in CF patients. Malnutrition is highly prevalent in the CF population and results from both poor food intake and excessive energy expenditure. A therapy which improves nutrition may therefore have a significant effect on the prognosis of this disease. Ghrelin is the only physiological circulating factor that is known to increase food intake. Administration of acylated ghrelin to humans increases both hunger and food intake and has been found to increase appetite in chronic disease states associated with anorexia and weight loss (such as cancer and chronic renal disease). From multiple animal and in vitro human studies, ghrelin also appears to have anti-inflammatory properties which would potentially benefit CF patients in whom a chronic inflammatory state promotes lung destruction, malnutrition and increases mortality. Ghrelin replacement may therefore improve nutrition and decrease the inflammatory burden in CF patients, leading to an improvement in life-expectancy. If ghrelin is identified as having an important pathophysiological role in CF it may lead to a future study of its efficacy as a therapeutic agent.
Design Methodology: The study has three sections:
- a cross sectional study of the levels of blood metabolic signals in participants with cystic fibrosis and healthy controls.
- a laboratory study of the effect of ghrelin on immune cells extracted from the blood of participants with cystic fibrosis and healthy controls
- a cross-over interventional study of repeated ghrelin administration in malnourished cystic fibrosis patients
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Storbritannia, CB23 3RE
- Rekruttering
- Papworth Hospital NHS Foundation Trust
-
Ta kontakt med:
- Andres R Floto, BM BSc, PhD
- Telefonnummer: 01480 830541
- E-post: andres.floto@papworth.nhs.uk
-
Ta kontakt med:
- Jane D Elliott, MPhil
- Telefonnummer: 01480 364495
-
Hovedetterforsker:
- Andres Floto, MB BChir, PhD, FRCP
-
Underetterforsker:
- Katie J Wynne, MB BChir, PhD, FRCP
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Cystic fibrosis
- BMI </=19 kg/m2
Exclusion Criteria:
- Needle phobia
- Pulmonary infection requiring intravenous antibiotics in the past 2 weeks-
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: saline injections
|
subcutaneous injection
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Appetite
Tidsramme: 4 weeks
|
4 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
vekt
Tidsramme: 4 uker
|
4 uker
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P01276
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Cystisk fibrose
-
National Institute of Allergy and Infectious Diseases...Fullført
Kliniske studier på ghrelin
-
Baker Heart and Diabetes InstituteFullført
-
David DalessioNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ukjent
-
Jenny Tong, MD, MPHTilbaketrukket
-
Esben Thyssen VestergaardFullført
-
University of PennsylvaniaFullført
-
University of PennsylvaniaFullført
-
Lars LundFullførtHjertesvikt med redusert ejeksjonsfraksjon HFrEF
-
University of PennsylvaniaFullført
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Fullført
-
Hvidovre University HospitalFullførtBariatrisk kirurgiDanmark